|
Expectation of Unpleasant Events in Anxiety Disorders Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Expectation of Unpleasant Events in Anxiety Disorders conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Expectation of Unpleasant Events in Anxiety Disorders Clinical research trials and Expectation of Unpleasant Events in Anxiety Disorders health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Expectation of Unpleasant Events in Anxiety Disorders. Expectation of Unpleasant Events in Anxiety Disorders Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Expectation of Unpleasant Events in Anxiety Disorders clinical trial. Human subjects often get the best healthcare possible for their Expectation of Unpleasant Events in Anxiety Disorders condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Expectation of Unpleasant Events in Anxiety Disorders  Expectation of Unpleasant Events in Anxiety Disorders
Expectation of Unpleasant Events in Anxiety Disorders
For Condition: Anxiety Disorders
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Fear and anxiety are normal responses to a threat. However, anxiety is considered abnormal when the response to the threat is excessive or inappropriate. This study will examine changes in the body and brain that occur during unpleasant learning experiences in healthy volunteers with high, moderate, and low levels of anxiety. A high degree of generalized anxiety is a component of many anxiety disorders and is regarded as a marker of vulnerability for these disorders. People with anxiety disorders and individuals with high degrees of anxiety have inappropriate expectations of unpleasant events. This study will investigate the development of expecting unpleasant events in healthy volunteers with varying degrees of anxiety using aversive conditioning models. A later phase of the study will enroll participants with anxiety disorders and compare their responses to those of healthy volunteers. Healthy volunteers who have no history of psychiatric or major medical illness will be enrolled in this study. Volunteers will come to the NIH Clinical Center three times for outpatient testing.
Details: High-generalized anxiety is a concomitant of many anxiety disorders and is often regarded as a vulnerability marker for these disorders. One characteristic of patients with anxiety disorders and high trait-anxious individuals is inappropriate expectancies of aversive events. The overall aim of the present protocol is to investigate mechanisms that may promote the development of these aversive expectancies using expectancy-based, associative-learning models. During aversive conditioning in which a phasic explicit-cue (e.g., a light) is repeatedly associated with an aversive unconditioned-stimulus (e.g., a shock), the organism develops fear to the explicit cue as well as to the environmental context in which the experiment took place. We have obtained preliminary evidence suggesting that contextual fear represents aspects of aversive states that are central to anxiety disorders. In this protocol, we seek further evidence for the relevance of contextual fear to anxiety disorders and, in particular, to the symptom of generalized anxiety. One important determinant of contextual fear in both humans and animals is predictability: contextual fear increases when aversive events (e.g., electric shock) are unpredictable, as opposed to when they are predictable. The present protocol will examine the role of predictability of aversive states and of conditioning on threat appraisal in anxious individuals. A second aim is to examine processes that may promote the development of contextual fear. Classical aversive-conditioning is an ideal technique to explore cognitive, attentional and emotional processes underlying the development of aversive expectations to explicit and contextual cues. We will attempt to relate conditioned performance to measures of 1) autonomic reactivity (orienting response and heart-rate variability) and 2) attentional bias. Substantial evidence suggests that autonomic reactivity has broad implication for cognitive and affective regulation and that attentional biases may imply a role in generating and/or maintaining maladaptive levels of anxiety. The study will be conducted in two separate groups of subjects: 1) healthy subjects high in trait anxiety and their age and sex matched, moderate, and low trait-anxiety counterparts, and 2) patients with panic disorder, generalized anxiety disorder, and specific phobia, and their aged-and sex-matched healthy controls. Currently, only healthy participants high, moderate, and low in trait anxiety (n=120) will be recruited and tested. Anxiety patients and their sex and age matched healthy counterparts will not be included until an appropriate plan for following and caring for psychiatric patients is formulated and ready for implementation. Therefore, hypothesis testing of predictions regarding trait anxiety will be possible before predictions specific to pathological anxiety can be tested.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients and Healthy Controls: a) Currently the study sample will consist of healthy subjects without a current or past history of psychiatric or major medical illness. b) Following implementation of an appropriate plan to care for psychiatric patients, this protocol will include patients with a primary diagnosis of generalized anxiety disorder, panic disorder, or specific phobia according to DSM-IV. c) All subjects will be between 18 and 55 years old. d) Male and female subjects will be included. e) All subjects must be able to give written informed consent prior to participation in this study. f) All eligible subjects must be in good physical health as confirmed by a complete physical exam (including normal vital signs), electrocardiogram, neurological exam, and routine laboratory tests of blood and urine. EXCLUSION CRITERIA: Healthy Subjects: a) Female subjects who are currently pregnant; b) Subjects who meet DSM-IV criteria for alcohol and/or substance abuse or substance dependence within 6 months prior to screening; c) Current or past Axis I psychiatric disorders as identified with the Structured Clinical Interview for DSM-IV-TR axis disorders, non-patient edition (SCID-np); d) History of any disease, which in the investigators' opinion may confound the results of the study including, but not limited to, history of organic mental disorders, seizure, or mental retardation; e) Subjects who take psychoactive medications or medications that can interefere with the study; f) Medical or neurological illnesses likely to interfere with the study. Patients: a) Patients who would be unable to comply with study procedures or assessments; b) Female patients who are currently pregnant; c) Specific phobia patients carrying a diagnosis of generalized anxiety disorder; d) Patients who meet DSM-IV criteria for alcohol and/or substance abuse or substance dependence within 6 months prior to screening; e) Patients who are currently on psychotropic medications. (Patients must be off medication for 2 weeks, 6 weeks for fluoxetine. Patients will not be taken off medications for the purpose of the study); f) Patients who are on a medication that may interfere with the study; g) Medical or nerological illnesses likely to interefere with the study; h) Patients will be excluded if they have a current or past history of any psychotic disorder, bipolar disorder, delirium, dementia, amnestic disorder not otherwise specified, any of the pervasive development disorders, or mental retardation; i) Patients with a current or past history of major depression that occurred before the onset of their anxiety disorder will be excluded from the study. Excluding all patients with comorbid major-depression was thought to be unrealistic given the high comorbidity-rates between anxiety disorders and major depression. Study results will be protected from the confounding influence of comorbid depression by statistically controlling for the variance in dependent measures asociated with this variable; j) Patients who either score above 38 on the Inventory of the Depressive Symptoms (IDS) or display significant suicidal ideation or behavior.
Total Enrollment: 240
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030093; 03-M-0093
Study Start Date: February 13, 2003
Record last reviewed: February 13, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055224
Other Anxiety Disorders Studies:
1. Treatment for Anxiety in Children
2. The Psychobiology of Childhood Temperament
3. Preventing Anxiety Disorders in Youth
4. Therapeutic Processes and Treatment Outcome in Adolescents with Anxiety Disorders
5. Cognitive and Drug Therapy for Drug-Resistant Depression
Related Studies:
Other Anxiety Disorders Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Expectation of Unpleasant Events in Anxiety Disorders
|
|
|
|
|
|
|
|
